CD8A and neoplasm: [99] demonstrated that intravenously injected MVA-MUC1 can generate MUC1-specific CD8+ T cells that inhibit tumor growth in RCC, and that the anti-tumor efficacy was further enhanced when combined with a Toll-like receptor 9 (TLR9) agonist.